Treatable Mechanisms in Asthma.
Journal
Molecular diagnosis & therapy
ISSN: 1179-2000
Titre abrégé: Mol Diagn Ther
Pays: New Zealand
ID NLM: 101264260
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
accepted:
12
01
2021
pubmed:
12
2
2021
medline:
26
10
2021
entrez:
11
2
2021
Statut:
ppublish
Résumé
Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potentially useful approach to personalize therapy for better outcomes. Nonetheless, there are still many problems related to the identification and validation of asthma phenotypes and endotypes. Alternatively, a precision-medicine strategy for the management of patients with airways disease that is free from the traditional diagnostic labels and based on identifying "treatable traits" in each patient might be preferable. However, it would represent a quite unsophisticated approach because the definition of a treatable trait is too imprecise. In fact, there is still no understanding of the mechanisms underlying treatable traits that allow directing any targeted therapies against any particular treatable trait. Fortunately, in-depth identification of underlying molecular pathways to guide targeted treatment in individual patients is in progress thanks to the improvement in big data management obtained from '-omic' sciences that is greatly increasing knowledge concerning asthma.
Identifiants
pubmed: 33570719
doi: 10.1007/s40291-021-00514-w
pii: 10.1007/s40291-021-00514-w
pmc: PMC7956930
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-121Références
National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Expert panel report 3: guidelines for the diagnosis and management of asthma. Section 2, p. 1. 2007. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.ht . Accessed 21 Oct 2020.
Lötvall J, Akdis CA, Bacharier LB, Bjermer L, Casale TB, Custovic A, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–60.
pubmed: 21281866
Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet. 2006;368(9537):804–13.
pubmed: 16935691
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–25.
pubmed: 22561835
Global initiative for asthma. 2020 GINA report, global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf . Accessed 21 Oct 2020.
Agache I, Akdis CA. Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes of allergic diseases. J Clin Investig. 2019;129(4):1493–503.
pubmed: 30855278
Santus P, Saad M, Damiani G, Patella V, Radovanovic D. Current and future targeted therapies for severe asthma: managing treatment with biologics based on phenotypes and biomarkers. Pharmacol Res. 2019;146:104296.
pubmed: 31173886
Chung KF. Defining phenotypes in asthma: a step towards personalised medicine. Drugs. 2014;74(7):719–28.
pubmed: 24797157
President’s Council of Advisors on Science and Technology. Priorities for personalized medicine. 2008. https://www.whitehouse.gov/files/documents/ostp/PCAST/pcast_report_v2.pdf . Accessed 21 Oct 2020.
Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med. 2012;366(6):489–91.
pubmed: 22256780
Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400.
pubmed: 28911920
Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat Rev Immunol. 2015;15(1):57–65.
pubmed: 25534623
pmcid: 4390063
Oishi K, Hirano T, Matsuda K, Hamada K, Uehara S, Suetake R, et al. The prevalence and clinical characteristics of T2-high and T2-low endotype of severe uncontrolled asthma distinguished by combining popular type-2 biomarkers (abstract). Eur Respir J. 2019;54:PA2749.
Jackson D, Aljamil N, Roxas C, Fernandes M, Green L, Kavanagh J, et al. P48 The ‘T2-low’ asthma phenotype: could it just be T2-high asthma treated with corticosteroids? (abstract). Thorax. 2018;73:A124–5.
Fitzpatrick AM, Chipps BE, Holguin F, Woodruff PG. T2-"low" asthma: overview and management strategies. J Allergy Clin Immunol Pract. 2020;8(2):452–63.
pubmed: 32037109
Muraro A, Lemanske RF Jr, Hellings PW, Akdis CA, Bieber T, Casale TB, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347–58.
pubmed: 27155030
Wenzel SE. Complex phenotypes in asthma: current definitions. Pulm Pharmacol Ther. 2013;26(6):710–5.
pubmed: 23880027
Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797–807.
pubmed: 27773852
Loza MJ, Djukanovic R, Chung KF, Horowitz D, Ma K, Branigan P, et al. Validated and longitudinally stable asthma phenotypes based on cluster analysis of the ADEPT study. Respir Res. 2016;17(1):165.
pubmed: 27978840
pmcid: 5159977
Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: Moving toward precision medicine. J Allergy Clin Immunol. 2019;144(1):1–12.
pubmed: 31277742
Chaudhuri R, McSharry C, Heaney LG, Niven R, Brightling CE, Menzies-Gow AN, et al. Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. Respir Med. 2016;118:46–52.
pubmed: 27578470
Principe S, Benfante A, Calzetta L, Rogliani P, Scichilone N. Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. World Allergy Organ J. 2019;12(11):100081.
pubmed: 31890084
pmcid: 6931205
Hsiao HP, Lin MC, Wu CC, Wang CC, Wang TN. Sex-specific asthma phenotypes, inflammatory patterns, and asthma control in a cluster analysis. J Allergy Clin Immunol Pract. 2019;7(2):556–67.
pubmed: 30170162
Fuhlbrigge AL, Castro M. Precision medicine in asthma - Using phenotypes to understand endotypes that lead us to new therapeutic options. J Allergy Clin Immunol Pract. 2020;8(2):496–7.
pubmed: 32037110
Li X. Hot Topic: Precision medicine for asthma—has the time come? Curr Allergy Asthma Rep. 2019;19(10):45.
pubmed: 31486903
Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic endotypes and phenotypes of asthma. J Allergy Clin Immunol Pract. 2020;8(2):429–40.
pubmed: 32037107
pmcid: 7569362
Chung KF, Adcock IM. Precision medicine for the discovery of treatable mechanisms in severe asthma. Allergy. 2019;74(9):1649–59.
pubmed: 30865306
Rogliani P, Calzetta L, Matera MG, Laitano R, Ritondo BL, Hanania NA, et al. Severe asthma and biological therapy: when, which, and for whom. Pulm Ther. 2020;6(1):47–66.
pubmed: 32048241
Sze E, Bhalla A, Nair P. Mechanisms and therapeutic strategies for non-T2 asthma. Allergy. 2020;75(2):311–25.
pubmed: 31309578
Agache I, Miller R, Gern JE, Hellings PW, Jutel M, Muraro A, et al. Emerging concepts and challenges in implementing the exposome paradigm in allergic diseases and asthma: a Practall document. Allergy. 2019;74(3):449–63.
pubmed: 30515837
Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–9.
pubmed: 26828055
McDonald VM, Fingleton J, Agusti A, Hiles SA, Clark VL, Holland AE, et al. Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur Respir J. 2019;53(5):1802058.
pubmed: 30846468
Tay TR, Hew M. Comorbid, “treatable traits” in difficult asthma: current evidence and clinical evaluation. Allergy. 2018;73(7):1369–82.
pubmed: 29178130
Hiles SA, Gibson PG, Agusti A, McDonald VM. Treatable traits that predict health status and treatment response in airway disease. J Allergy Clin Immunol Pract. 2020. https://doi.org/10.1016/j.jaip.2020.09.046 .
doi: 10.1016/j.jaip.2020.09.046
pubmed: 33039647
Clark VL, Gibson PG, Genn G, Hiles SA, Pavord ID, McDonald VM. Multidimensional assessment of severe asthma: a systematic review and meta-analysis. Respirology. 2017;22(7):1262–75.
pubmed: 28776330
McDonald VM, Clark VL, Cordova-Rivera L, Wark PAB, Baines KJ, Gibson PG. Targeting treatable traits in severe asthma: a randomised controlled trial. Eur Respir J. 2020;55(3):1901509.
pubmed: 31806719
Simpson AJ, Hekking PP, Shaw DE, Fleming LJ, Roberts G, Riley JH, et al. Treatable traits in the European U-BIOPRED adult asthma cohorts. Allergy. 2019;74(2):406–11.
pubmed: 30307629
McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, et al. Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respirology. 2019;24(1):37–47.
pubmed: 30230137
Ulrik CS, Vijverberg S, Hanania NA, Diamant Z. Precision medicine and treatable traits in chronic airway diseases—where do we stand? Curr Opin Pulm Med. 2020;26(1):33–9.
pubmed: 31644440
Ray A, Camiolo M, Fitzpatrick A, Gauthier M, Wenzel SE. Are we meeting the promise of endotypes and precision medicine in asthma? Physiol Rev. 2020;100(3):983–1017.
pubmed: 31917651
Mogensen I, James A, Malinovschi A. Systemic and breath biomarkers for asthma: an update. Curr Opin Allergy Clin Immunol. 2020;20(1):71–9.
pubmed: 31652141
Coverstone AM, Seibold MA, Peters MC. Diagnosis and management of T2-high asthma. J Allergy Clin Immunol Pract. 2020;8(2):442–50.
pubmed: 32037108
Haughney J, Morice A, Blyth KG, Lee AJ, Coutts A, McKnight E, et al. A retrospective cohort study in severe asthma describing commonly measured biomarkers: eosinophil count and IgE levels. Respir Med. 2018;134:117–23.
pubmed: 29413497
Pavlidis S, Takahashi K, Kwong FNK, Xie J, Hoda U, Sun K, et al. “T2-high” in severe asthma related to blood eosinophil, exhaled nitric oxide and serum periostin. Eur Respir J. 2019;53(1):1800938.
pubmed: 30578390
Roth M, Stolz D. Biomarkers and personalised medicine for asthma. Eur Respir J. 2019;53(1):1802094.
pubmed: 30606766
Alving K, Diamant Z, Lucas S, Magnussen H, Pavord ID, Piacentini G, et al. Point-of-care biomarkers in asthma management: time to move forward. Allergy. 2020;75(4):995–7.
pubmed: 31505025
Hanania NA, Wenzel S, Rosén K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804–11.
pubmed: 23471469
Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106(11):1494–500.
pubmed: 22884459
Calzetta L, Matera MG, Coppola A, Rogliani P. Prospects for severe asthma treatment. Curr Opin Pharmacol. 2020;56:52–60.
pubmed: 33310456
Diamant Z, Vijverberg S, Alving K, Bakirtas A, Bjermer L, Custovic A, et al. Toward clinically applicable biomarkers for asthma: an EAACI position paper. Allergy. 2019;74(10):1835–51.
pubmed: 30953574
Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486–96.
pubmed: 29782217
Simpson JL, Powell H, Boyle MJ, Scott RJ, Gibson PG. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.
pubmed: 17947611
Bagnasco D, Ferrando M, Varricchi G, Puggioni F, Passalacqua G, Canonica GW. Anti-interleukin 5 (IL-5) and IL-5Ra biological drugs: efficacy, safety, and future perspectives in severe eosinophilic asthma. Front Med (Lausanne). 2017;4:135.
pubmed: 28913336
pmcid: 5583162
British Thoracic Society/Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline; 2016. http://www.brit-thoracic.org.uk . Accessed 5 Jan 2021.
Irwin RS, Richardson ND. Side effects with inhaled corticosteroids: the physician’s perception. Chest. 2006;130(1 Suppl):41S-53S.
pubmed: 16840367
Beasley R, Harper J, Bird G, Maijers I, Weatherall M, Pavord ID. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am J Respir Crit Care Med. 2019;199(12):1471–7.
pubmed: 30645143
Abdel-Aziz MI, Neerincx AH, Vijverberg SJ, Kraneveld AD, Maitland-van der Zee AH. Omics for the future in asthma. Semin Immunopathol. 2020;42(1):111–26.
pubmed: 31942640
Colas L, Hassoun D, Magnan A. Needs for systems approaches to better treat individuals with severe asthma: predicting phenotypes and responses to treatments. Front Med (Lausanne). 2020;7:98.
pubmed: 32296705
pmcid: 7137032
Chung KF. Personalised medicine in asthma: time for action. Eur Respir Rev. 2017;26(145):170064.
pubmed: 28954768